Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 1/2016

Open Access 01-06-2016 | Review

Solid Platelet Rich Plasma in Corneal Surgery

Authors: Francisco Arnalich, Alejandra E. Rodriguez, Alvaro Luque-Rio, Jorge L. Alio

Published in: Ophthalmology and Therapy | Issue 1/2016

Login to get access

Abstract

Abstract

Solid eye platelet-rich plasma (E-PRP) concentrates platelets in a small volume of plasma which contains a high concentration of important growth factors and cell adhesion molecules. These cell adhesion molecules and growth factors occupy a major role in wound healing and enhance the physiological procedure at the site of the injury or the surgery. There are different materials used to tectonically maintain the solid clot attached at the site where treatment is necessary. Although AM may be used for this purpose, other biomaterials such a bovine pericardium or autologous fibrin membrane are at least as effective with less interdonor variations, no biological hazards, providing a better surgical alternative than the biologically so variable amniotic membrane patch. Solid platelet-rich plasma in the form obtained in ophthalmology, E-PRP, is a reliable and effective surgical coadjuvant to promote corneal wound healing in severe corneal ulcers and corneal perforations, and may be associated with other ocular surface reconstruction procedures.

Funding

Supported in part by a grant from the Spanish Ministry of Science and Innovation, Centro para el Desarrollo Tecnológico Industrial (CDTI), CENIT: “Customized Eye Care”, CeyeC (CEN-20091021).
Literature
1.
Nakamura T, Inatomi T, Sotozono C, Koizumi N, Kinoshita S. Ocular surface reconstruction using stem cell and tissue engineering. Prog Retin Eye Res. 2016;51:187–207.CrossRefPubMed
2.
Hick S, Demers PE, Brunette I, La C, Mabon M, Duchesne B. Amniotic membrane transplantation and fibrin glue in the management of corneal ulcers and perforations: a review of 33 cases. Cornea. 2005;24(4):369–77.CrossRefPubMed
3.
Jhanji V, Young AL, Mehta JS, Sharma N, Agarwal T, Vajpayee RB. Management of corneal perforation. Surv Ophthalmol. 2011;56(6):522–38.CrossRefPubMed
4.
Alio JL, Rodriguez AE, WróbelDudzińska D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol. 2015;26(4):325–32.CrossRefPubMed
5.
Petznick A, Tong L, Chung R, Wang JC, Koh M, Salleh R, Waduthantri S. Autologous plasma eyedrops prepared in a closed system: a treatment for dry eye. Eye. 2013;27(9):1102.CrossRefPubMedPubMedCentral
6.
Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of “eye platelet rich plasma” (E-PRP) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012;13(7):1257–65.CrossRefPubMed
7.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–8.CrossRefPubMed
8.
9.
Anitua E, Sanchez M, Orive G, Andia I. Delivering growth factors for therapeutics. Trends Pharmacol Sci. 2008;29(1):37–41.CrossRefPubMed
10.
Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91(1):4–15.PubMed
11.
Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27(4):459–61.CrossRefPubMed
12.
Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–9.CrossRefPubMed
13.
Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115–20.CrossRefPubMed
14.
Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20(8):807–10.CrossRefPubMed
15.
Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transpl. 2003;31(7):579–83.CrossRef
16.
Noda-Tsuruya T, Asano-Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. J Refract Surg. 2006;22(1):61–6.PubMed
17.
Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens–Johnson syndrome. Am J Ophthalmol. 1996;122(1):38–52.CrossRefPubMed
18.
Tsubota K, Shimazaki J. Surgical treatment of children blinded by Stevens–Johnson syndrome. Am J Ophthalmol. 1999;128(5):573–81.CrossRefPubMed
19.
Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sci. 2006;47(6):2438–44.CrossRefPubMed
20.
Anitua E, Sanchez M, Nurden AT, Nurden P, Orive G, Andia I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24(5):227–34.CrossRefPubMed
21.
Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532–48.PubMed
22.
Anitua E, Andia I, Sanchez M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005;23(2):281–6.CrossRefPubMed
23.
Anitua E, Sanchez M, Nurden AT, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology. 2007;46(12):1769–72.CrossRefPubMed
24.
Anitua E, Sanchez M, Zalduendo MM, et al. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009;42(2):162–70.CrossRefPubMed
25.
Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmol. 2007;114(7):1286–93.CrossRef
26.
Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39(3):124–9.CrossRefPubMed
27.
Alio JL, Pastor S, Ruiz-Colecha J, Rodriguez A, Artola A. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J Refract Surg. 2007;23(6):617–9.PubMed
28.
Anitua E. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract Proced Aesthet Dent. 2001;13(6):487–93 (quiz 487–493).PubMed
29.
Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259–72.CrossRefPubMed
30.
Intini G. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials. 2009;30(28):4956–66.CrossRefPubMed
31.
Anitua E, Orive G, Pla R, Roman P, Serrano V, Andia I. The effects of PRGF on bone regeneration and on titanium implant osteointegration in goats: a histologic and histomorphometric study. J Biomed Mater Res A. 2009;91(1):158–65.CrossRefPubMed
32.
Roldan JC, Jepsen S, Schmidt C, et al. Sinus floor augmentation with simultaneous placement of dental implants in the presence of platelet-rich plasma or recombinant human bone morphogenetic protein-7. Clin Oral Implants Res. 2004;15(6):716–23.CrossRefPubMed
33.
Garg AK, Gargenese D, Peace I. Using platelet-rich plasma to develop an autologous membrane for growth factor delivery in dental implant therapy. Dent Implantol Update. 2000;11(6):41–4.PubMed
34.
Sanchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol. 2008;26(5):910–3.PubMed
35.
Sanchez M, Anitua E, Azofra J, Andia I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007;35(2):245–51.CrossRefPubMed
36.
Mazor Z, Peleg M, Garg AK, Luboshitz J. Platelet-rich plasma for bone graft enhancement in sinus floor augmentation with simultaneous implant placement: patient series study. Implant Dent. 2004;13(1):65–72.CrossRefPubMed
37.
Velich N, Nemeth Z, Hrabak K, Suba Z, Szabo G. Repair of bony defect with combination biomaterials. J Craniofac Surg. 2004;15(1):11–5.CrossRefPubMed
38.
Siebrecht MA, De Rooij PP, Arm DM, Olsson ML, Aspenberg P. Platelet concentrate increases bone ingrowth into porous hydroxyapatite. Orthopedics. 2002;25(2):169–72.PubMed
39.
Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am. 2002;84-A(6):1032–44.PubMed
40.
Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009;91(8):987–96.CrossRefPubMed
41.
Alio JL, Rodriguez AE, Martinez LM. Bovine pericardium membrane (Tutopatch) combined with solid platelet-rich plasma for the management of perforated corneal ulcers. Cornea. 2013;32(5):619–24.CrossRefPubMed
42.
Hopkinson A, McIntosh RS, Tighe PJ, James DK, Dua HS. Amniotic membrane for ocular surface reconstruction: donor variations and the effect of handling on TGF-beta content. Invest Ophthalmol Vis Sci. 2006;47(10):4316–22.CrossRefPubMed
43.
Us MH, Sungun M, Sanioglu S, et al. A retrospective comparison of bovine pericardium and polytetrafluoroethylene patch for closure of ventricular septal defects. J Int Med Res. 2004;32(2):218–21.CrossRefPubMed
44.
Filippi R, Schwarz M, Voth D, Reisch R, Grunert P, Perneczky A. Bovine pericardium for duraplasty: clinical results in 32 patients. Neurosurg Rev. 2001;24(2–3):103–7.CrossRefPubMed
45.
Schmal F, Basel T, Grenzebach UH, Thiede O, Stoll W. Preseptal transconjunctival approach for orbital floor fracture repair: ophthalmologic results in 209 patients. Acta Otolaryngol. 2006;126(4):381–9.CrossRefPubMed
46.
Gupta M, Lyon F, Singh AD, Rundle PA, Rennie IG. Bovine pericardium (Tutopatch) wrap for hydroxyapatite implants. Eye. 2007;21(4):476–9.PubMed
47.
Alio JL, Rodriguez AE, Martinez LM, Rio AL. Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study. JAMA Ophthalmol. 2013;131(6):745–51.CrossRefPubMed
48.
Setlik DE, Seldomridge DL, Adelman RA, Semchyshyn TM, Afshari NA. The effectiveness of isobutyl cyanoacrylate tissue adhesive for the treatment of corneal perforations. Am J Ophthalmol. 2005;140(5):920–1.CrossRefPubMed
49.
Portnoy SL, Insler MS, Kaufman HE. Surgical management of corneal ulceration and perforation. Surv Ophthalmol. 1989;34(1):47–58.CrossRefPubMed
50.
51.
Nobe JR, Moura BT, Robin JB, Smith RE. Results of penetrating keratoplasty for the treatment of corneal perforations. Arch Ophthalmol. 1990;108(7):939–41.CrossRefPubMed
Metadata
Title
Solid Platelet Rich Plasma in Corneal Surgery
Authors
Francisco Arnalich
Alejandra E. Rodriguez
Alvaro Luque-Rio
Jorge L. Alio
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2016
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-016-0051-9

Other articles of this Issue 1/2016

Ophthalmology and Therapy 1/2016 Go to the issue

Review

The Treatment Paradigm for the Implantable Miniature Telescope

Case Report

Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma

Original Research

Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management

Original Research

Pharmacological Treatment of Presbyopia by Novel Binocularly Instilled Eye Drops: A Pilot Study

Case Series

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up

Original Research

Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN® (Fluocinolone Acetonide)

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits